Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17100113 | 0.93 | LTA4H (0.39) | LTA4HACACBPPARACHRNB2CHRNB4 | |
| SCHEMBL17100290 | 0.81 | PPARA (0.36) | LTA4HPPARASLC2A1CHRNB2CHRNB4 | |
| SCHEMBL17111330 | 0.80 | TSHR (0.43) | TDP1L3MBTL1 | |
| SCHEMBL17100236 | 0.77 | LTA4H (0.35) | LTA4HPPARACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL8417793 | 0.75 | LTA4H (0.68) | LTA4H | |
| SCHEMBL8685113 | 0.74 | LTA4H (0.39) | LTA4HCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL13303326 | 0.72 | LTA4H (0.55) | LTA4HSLC2A1 | |
| SCHEMBL7267685 | 0.72 | LTA4H (0.57) | GPR88LTA4HL3MBTL1 | |
| SCHEMBL5104539 | 0.72 | ALOX5 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4L3MBTL1 | |
| SCHEMBL18682252 | 0.72 | NR5A1 (0.50) | GPR88LTA4HSLC2A1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3119760-A1 | PIPERIDINE-DIONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2015140133-A1 | PIPERIDINE-DIONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015142903-A2 | METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | GPR88 629/4885LTA4H 2821/4885ACACB 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.